ISU Abxis Co., Ltd. (KOSDAQ:086890)

South Korea flag South Korea · Delayed Price · Currency is KRW
5,160.00
-70.00 (-1.34%)
Feb 13, 2025, 9:00 AM KST
-9.63%
Market Cap 179.16B
Revenue (ttm) 56.18B
Net Income (ttm) -5.05B
Shares Out 35.90M
EPS (ttm) -144.02
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 187,558
Average Volume 156,541
Open 5,160.00
Previous Close 5,230.00
Day's Range 5,080.00 - 5,310.00
52-Week Range 3,945.00 - 8,000.00
Beta 0.75
RSI 57.10
Earnings Date Mar 13, 2025

About ISU Abxis

ISU Abxis Co., Ltd., a biopharmaceutical company, develops and markets products for the treatment of cancer and rare diseases worldwide. The company offers Abcertin, an imiglucerase for injection that is used as long-term enzyme replacement therapy in patients with a confirmed diagnosis of Type 1 Gaucher disease; Fabagal, an agalsidase beta for injection, which is used as a long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease; Clotinab, an abciximab that is used as an adjunct to percutaneous coronary inte... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2001
Employees 95
Stock Exchange KOSDAQ
Ticker Symbol 086890
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.